Selena Zhang's questions to Mirum Pharmaceuticals Inc (MIRM) leadership • Q1 2025
Question
On behalf of Mike Ulz, Selena Zhang asked for an update on LIVMARLI's market access versus competitors and how step-through policies are evolving for both Alagille syndrome and PFIC indications.
Answer
President and Chief Operating Officer Peter Radovich stated that U.S. access for LIVMARLI is very strong and not a barrier. He acknowledged that while some policies give LIVMARLI a preferential step-through position, the primary drivers of its success are its strong clinical value proposition and the comprehensive support Mirum provides.